ClinicalTrials.gg
CompletedNCT03452228Updated Feb 16, 2023Results posted

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

A Phase 2 interventional study of evinacumab and Placebo in Severe Hypertriglyceridemia (sHTG), sponsored by Regeneron Pharmaceuticals. Completed at 17 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-16.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.

Enrollment
70th of 145
52 · median 52
Started
2018
with 7 others
Phase 2
45 of 150
4 open now
Registered
107th of 150
by date
Lead sponsor
4 of 150
Regeneron Pharmaceuticals

Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 70th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2018, is one of 45 in phase 2, and was the 107th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertriglyceridemia with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.

03

Conditions studied

  • Severe Hypertriglyceridemia (sHTG)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Previous documentation in the patient's medical records of a fasting serum TG measurement ≥ 1000 mg/dL (11.3 mmol/L) on more than 1 occasion, and all fasting TG values ≥500 mg/dL (5.6 mmol/L) at screening
  2. History of a hospitalization and diagnosis of acute pancreatitis in the past 10 years
  3. On stable lipid-modifying diet with or without medications (eg, statins, niacin, omega-3 fatty acids). Lipid-modifying diet and doses of medications should be stable for at least 4 weeks (6 weeks for fibrates, 8 weeks for PCSK9 inhibitors) prior to screening
  4. (BMI) of 18-40 kg/m2

Key Exclusion Criteria:

  1. A hospital or clinic discharge diagnosis of acute pancreatitis within 12 weeks of screening
  2. Lipid apheresis or plasma exchange treatment within the last 4 weeks or plans to undergo apheresis or plasma exchange during the time frame of the study
  3. History of class 3/4 heart failure at any time in the past, or hospitalization for heart failure, diagnosis of a myocardial infarction, stroke, (TIA), unstable angina, Coronary artery bypass surgery (CABG), Percutaneous coronary intervention (PCI), carotid surgery/stenting within 3 months before the screening visit
  4. History of bleeding disorders, esophageal varices, heparin induced thrombocytopenia, or to receiving heparin (eg, allergic reaction to heparin)
  5. Previous treatment with Glybera® in the past 5 years or treatment with lomitapide or mipomersen in the past 6 months
  6. Pregnant or breast feeding women

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    evinacumab

    Drug: evinacumab

  • Experimental
    Placebo

    Drug: Placebo

Interventions

  • Administered by Intravenous (IV)

    Also known as: REGN1500

  • DrugPlacebo

    Administered by Intravenous (IV)

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants

    For participants randomized to evinacumab treatment group, baseline (Week 0) TG was defined as the geometric mean of all available TG results at day -28, day -14 and week 0; for participants randomized to placebo treatment group, baseline (Week 12) TG was defined as the geometric mean of all available TG results at weeks 6, 8, and 12.

    Time frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP

Secondary outcomes

  1. Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group

    Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab overall group during DBTP and SBTP was reported.

    Time frame: DBTP: Baseline, Weeks 2, 4, 6, 8, 12; SBTP: Weeks 16, 20, and 24

  2. Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3

    Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab in actual cohorts 1, 2, and 3 participants were reported.

    Time frame: Weeks 2, 4, 6, 8, 12, 16, 20, and 24

  3. Change From Baseline in Total Score of Participants Reported Abdominal and Gastrointestinal (GI) Symptoms Using Hypertriglyceridemia and Acute Pancreatitis Symptom Scale (HAP-SS)

    HAP-SS: 19-item measure of symptoms with a 24-hour recall period. 4 pain items were captured on 0-10-point severity NRS, each scored 0 (No pain) to 10 (Worst possible pain), while 15 non-pain items captured on 5-point frequency Likert scale, each scored from 1 (None of the time) to 5 (All of the time). Pain domain 4 items: stomach pain average, worst stomach pain, worst back pain, stomach pain after eating (score range: 0 to 40). Abdominal symptoms domain 6 items: bloated, nausea, vomiting, passed excessive gas, diarrhea, light-colored or greasy stool (score range: 6 to 30). Physical symptoms domain 5 items: fever, insomnia, excessive sweating, dizziness, racing heart rate (score range 5 to 25). Other symptoms domain 4 items: fatigue, loss of appetite, hungry after eating, felt full after eating a small amount (score range 4 to 20). All items were transformed on to total score ranges from 0 (no symptoms) to 100 (severe symptoms). Negative change indicates better condition.

    Time frame: Baseline, Week 12 (DBTP), Week 24 (SBTP)

  4. Change From Baseline in Total Score of Participants Reported Dietary Behavior Questionnaire (HAP-DB)

    Dietary habits and impact were measured by the Hypertriglyceridemia and Acute Pancreatitis Dietary Behavior (HAP-DB) questionnaire, a 6- item measure of dietary behavior that had a 24-hour recall period using a 5-point frequency Likert scale (1= None of the time to 5= All of the time) and a dietary impact total score, ranging from 6 (no impact) to 30 (severe impact). The six HAP-DB items were: 1 -amount of food eaten), 2 -fatty or greasy food), 3 -carbohydrates), i4 (-sugar or sugary foods), 5 -alcohol intake), 6 -skipped meal). The total score was calculated as the sum of the six item scores and then transformed to a 0-100 score, where lower score indicates less of an issue with dietary behaviors. Transformed score = 100 \* (score - minimum possible score) / (maximum - minimum possible score). Change from baseline in total score of participants reported daily dietary habits and impact questionnaire during DBTP and SBTP was reported.

    Time frame: Baseline, Week 12 (DBTP), Week 24 (SBTP)

  5. DBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through 18F-2-Fluoro-2-Deoxy-D Glucose Positron Emission Tomography (18F-FDG-PET) Imaging Following 12 Weeks of Treatment With Evinacumab Assessed by 18F-FDG SUVmax and SUVmean

    18F-FDG-PET is a molecular imaging modality that has demonstrated high sensitivity in the in vivo detection of glycolytic tissues, including tumors and inflammatory foci. 18F-FDG PET has been applied in a clinical setting to the assessment of inflammation for a variety of indications, including auto immune pancreatitis, atherosclerosis and infection. 18F-FDG-PET was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Here, SUVmax was standardized uptake values maximum and SUVmean was mean standardized uptake values were reported.

    Time frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP

  6. DBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) Following 12 Weeks of Treatment With Evinacumab Assessed by Apparent Diffusion Coefficient (ADC)

    In DW-MRI the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 cubic millimeter (mm\^3). Normal pancreas ADCs were considered as (1.77±0.32)\*103 square-millimeters per second (mm\^2/sec) while acute pancreatitis ADCs were (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring projected inflammatory changes in pancreas. DW-MRI was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Change from baseline in degree of pancreatic injury/inflammation through DW-MRI following 12 weeks of treatment with evinacumab assessed by ADC was reported.

    Time frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP

  7. SBTP: Change From Baseline to Degree of Pancreatic Injury/Inflammation Through DW-MRI Following 24 Weeks of Treatment With Evinacumab as Assessed by ADC

    In DW-MRI, the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 mm\^3. Normal pancreas ADCs were considered as (1.77±0.32)\*103 mm\^2/sec while acute pancreatitis ADCs are (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring the projected inflammatory changes in the pancreas. Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 24 weeks of treatment with evinacumab assessed by ADC was reported.

    Time frame: Baseline (Week 0 DBTP), Week 24 (SBTP)

  8. Total Evinacumab Concentration in Serum

    Concentrations of total evinacumab in serum by time and DBTP treatment group reported

    Time frame: Up to 44 weeks

  9. Total Angiopoietin-like (ANGPTL3) Concentration in Serum

    Concentrations of total ANGPTL3 in serum by time and DBTP treatment group reported

    Time frame: Up to 44 weeks

  10. Number of Participants With Antidrug Antibodies (ADA)

    ADA were classified as the following: 1) Negative any time (negative in ADA assay at all time points); 2) Pre-existing immunoreactivity (ADA positive response at baseline with all post treatment ADA results negative or ADA positive response at baseline with all post treatment responses less than 9-fold of baseline titer levels); 3) Treatment-boosted Response (ADA positive response in assay post first dose that is at least 9-fold over baseline titer levels, when baseline results were positive); 4) Treatment-emergent ADA response (ADA positive response post first dose, when baseline results were negative or missing). Number of participants with ADA by DBTP treatment group reported.

    Time frame: Up to 44 weeks

  11. DBTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the DBTP reported.

    Time frame: From first dose of DB treatment to day of last dose of DB treatment + 24 weeks (if not proceeding to SBTP) or up to day before first dose of SB treatment in SBTP

  12. SBTP: Number of Participants With TEAEs and Serious TEAEs

    TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the SBTP reported.

    Time frame: From day of first SB study treatment to day of last SB treatment + 24 weeks

  13. Number of Participants With Liver Function Laboratory Abnormalities in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Total Bilirubin

    The number of participants with laboratory abnormalities in ALT, AST, ALP, and total bilirubin that fell into the pre-defined potentially clinically significant value (PCSV) categories reported: ALT: greater than (\>)2 upper limit of normal (ULN) and baseline (BL) less than or equal to (\<=) 2 ULN, less than (\>) 3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline ≤ 10 ULN, \>20 ULN and baseline \<= 20 ULN; AST: \>2 ULN and baseline ≤ 2 ULN, \>3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline \<= 10 ULN, \>20 ULN and baseline \<= 20 ULN; ALP: \> 1.5 ULN and baseline \<= 1.5 ULN; Total Bilirubin (TB): \> 1.5 ULN and baseline \<= 1.5 ULN, \> 2 ULN and baseline \<= 2 ULN.

    Time frame: Baseline up to 44 weeks

07

Results

Posted Feb 16, 2023

Participant flow

A total of 17 centers enrolled participants in Italy, Canada, the United Kingdom of Great Britain and Northern Ireland, and the United States.

Double-Blind Treatment Period (12 Weeks)
Participant flow — Double-Blind Treatment Period (12 Weeks)
MilestonePlacebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Evinacumab 15 mg/kg (SBTP)
Started17350
Treated16350
Actual cohort 15120
Actual cohort 2690
Actual cohort 35140
Completed15320
Not completed230
Withdrew: Adverse event020
Withdrew: Lost to follow-up110
Withdrew: Randomized but not treated100
Single-Blind Treatment Period (12 Weeks)
Participant flow — Single-Blind Treatment Period (12 Weeks)
MilestonePlacebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Evinacumab 15 mg/kg (SBTP)
Started0047
Treated0047
Actual cohort 1: db placebo to sb evinacumab004
Actual cohort 1: db evinacumab to sb evinacumab0011
Actual cohort 2: db placebo to sb evinacumab006
Actual cohort 2: db evinacumab to sb evinacumab009
Actual cohort 3: db placebo to sb evinacumab005
Actual cohort 3: db evinacumab to sb evinacumab0012
Completed0043
Not completed004
Withdrew: Withdrawal by subject004

Outcome measures

PrimaryPercent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants

For participants randomized to evinacumab treatment group, baseline (Week 0) TG was defined as the geometric mean of all available TG results at day -28, day -14 and week 0; for participants randomized to placebo treatment group, baseline (Week 12) TG was defined as the geometric mean of all available TG results at weeks 6, 8, and 12.

Time frame:
Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants
Percent ChangeActual Cohort 3: DB Placebo/SB Evinacumab IV 15mg/kg Q4WActual Cohort 3: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W
Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants19.2 ± 99.1-37.2 ± 42.9
Statistical analysis
  • Actual Cohort 3: DB Placebo/SB Evinacumab IV 15mg/kg Q4W · Median difference (final values): -43.5 · 95% CI -89.4 to 1238.9
  • Actual Cohort 3: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W · Median difference (final values): -75.5 · 95% CI -82.2 to 121.2
SecondaryPercent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group

Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab overall group during DBTP and SBTP was reported.

Time frame:
DBTP: Baseline, Weeks 2, 4, 6, 8, 12; SBTP: Weeks 16, 20, and 24
Reported as:
Mean · Percent Change
Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group
Percent ChangePlacebo Q4W (DBTP)Evinacumab IV 15mg/kg Q4W (DBTP)Evinacumab IV 15mg/kg Q4W (SBTP)
Percent change at Week 21.99 ± 45.687-51.38 ± 33.160—
Percent change at Week 4-3.52 ± 41.029-43.70 ± 39.119—
Percent change at Week 692.56 ± 262.368-52.69 ± 40.214—
Percent change at Week 84.83 ± 38.941-32.86 ± 64.787—
Percent change at Week 1217.47 ± 47.610-42.03 ± 61.086—
Percent change at Week 16——-39.23 ± 46.026
Percent change at Week 20——-38.09 ± 49.070
Percent change at Week 24——-35.86 ± 65.011
SecondaryPercent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3

Percent change from baseline in fasting TG level following 2 to 24 weeks of repeated IV doses of evinacumab in actual cohorts 1, 2, and 3 participants were reported.

Time frame:
Weeks 2, 4, 6, 8, 12, 16, 20, and 24
Reported as:
Median · Percent Change
Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3
Percent ChangeActual Cohort 1: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4WActual Cohort 2: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4WActual Cohort 3: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W
Percent change at Week 2-28.3 (-40.3 to -6.5)-77.5 (-81.2 to -58.9)-74.4 (-84.2 to -37.1)
Percent change at Week 4-19.0 (-69.6 to -2.7)-48.0 (-76.2 to -29.2)-70.3 (-83.4 to -50.2)
Percent change at Week 6-47.1 (-59.1 to -5.6)-84.6 (-85.7 to -61.3)-71.3 (-87.0 to -39.5)
Percent change at Week 8-29.5 (-72.0 to 4.8)-69.2 (-72.2 to -58.4)-62.5 (-84.8 to 48.0)
Percent change at Week 12-27.7 (-68.5 to 2.2)-64.8 (-84.5 to -41.8)-81.7 (-90.5 to -21.7)
Percent change at Week 16-16.2 (-56.7 to 29.3)-71.3 (-80.8 to -57.1)-80.4 (-87.2 to -37.3)
Percent change at Week 20-37.2 (-49.9 to -8.8)-65.5 (-70.2 to -45.8)-75.7 (-88.1 to -6.6)
Percent change at Week 24-7.7 (-31.8 to 9.1)-75.7 (-82.3 to -57.1)-71.4 (-86.5 to -54.0)
SecondaryChange From Baseline in Total Score of Participants Reported Abdominal and Gastrointestinal (GI) Symptoms Using Hypertriglyceridemia and Acute Pancreatitis Symptom Scale (HAP-SS)

HAP-SS: 19-item measure of symptoms with a 24-hour recall period. 4 pain items were captured on 0-10-point severity NRS, each scored 0 (No pain) to 10 (Worst possible pain), while 15 non-pain items captured on 5-point frequency Likert scale, each scored from 1 (None of the time) to 5 (All of the time). Pain domain 4 items: stomach pain average, worst stomach pain, worst back pain, stomach pain after eating (score range: 0 to 40). Abdominal symptoms domain 6 items: bloated, nausea, vomiting, passed excessive gas, diarrhea, light-colored or greasy stool (score range: 6 to 30). Physical symptoms domain 5 items: fever, insomnia, excessive sweating, dizziness, racing heart rate (score range 5 to 25). Other symptoms domain 4 items: fatigue, loss of appetite, hungry after eating, felt full after eating a small amount (score range 4 to 20). All items were transformed on to total score ranges from 0 (no symptoms) to 100 (severe symptoms). Negative change indicates better condition.

Time frame:
Baseline, Week 12 (DBTP), Week 24 (SBTP)
Reported as:
Mean · Score on a Scale
Change From Baseline in Total Score of Participants Reported Abdominal and Gastrointestinal (GI) Symptoms Using Hypertriglyceridemia and Acute Pancreatitis Symptom Scale (HAP-SS)
Score on a ScalePlacebo IV Q4W (DBTP)Evinacumab IV 15mg/kg (DBTP)Evinacumab IV 15mg/kg (SBTP)
DBTP: Change at Week 12-0.69 ± 6.930-0.74 ± 5.102—
SBTP: Change at Week 24——-0.12 ± 5.033
SecondaryChange From Baseline in Total Score of Participants Reported Dietary Behavior Questionnaire (HAP-DB)

Dietary habits and impact were measured by the Hypertriglyceridemia and Acute Pancreatitis Dietary Behavior (HAP-DB) questionnaire, a 6- item measure of dietary behavior that had a 24-hour recall period using a 5-point frequency Likert scale (1= None of the time to 5= All of the time) and a dietary impact total score, ranging from 6 (no impact) to 30 (severe impact). The six HAP-DB items were: 1 -amount of food eaten), 2 -fatty or greasy food), 3 -carbohydrates), i4 (-sugar or sugary foods), 5 -alcohol intake), 6 -skipped meal). The total score was calculated as the sum of the six item scores and then transformed to a 0-100 score, where lower score indicates less of an issue with dietary behaviors. Transformed score = 100 \* (score - minimum possible score) / (maximum - minimum possible score). Change from baseline in total score of participants reported daily dietary habits and impact questionnaire during DBTP and SBTP was reported.

Time frame:
Baseline, Week 12 (DBTP), Week 24 (SBTP)
Reported as:
Mean · Score on a Scale
Change From Baseline in Total Score of Participants Reported Dietary Behavior Questionnaire (HAP-DB)
Score on a ScalePlacebo IV Q4W (DBTP)Evinacumab IV 15mg/kg (DBTP)Evinacumab IV 15mg/kg (SBTP)
DBTP: Change at Week 12-2.267 ± 5.58972.021 ± 15.2152—
SBTP: Change at Week 24——-1.255 ± 7.7864
SecondaryDBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through 18F-2-Fluoro-2-Deoxy-D Glucose Positron Emission Tomography (18F-FDG-PET) Imaging Following 12 Weeks of Treatment With Evinacumab Assessed by 18F-FDG SUVmax and SUVmean

18F-FDG-PET is a molecular imaging modality that has demonstrated high sensitivity in the in vivo detection of glycolytic tissues, including tumors and inflammatory foci. 18F-FDG PET has been applied in a clinical setting to the assessment of inflammation for a variety of indications, including auto immune pancreatitis, atherosclerosis and infection. 18F-FDG-PET was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Here, SUVmax was standardized uptake values maximum and SUVmean was mean standardized uptake values were reported.

Time frame:
Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP
Reported as:
Mean · gram/milliliter (g/ml)
DBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through 18F-2-Fluoro-2-Deoxy-D Glucose Positron Emission Tomography (18F-FDG-PET) Imaging Following 12 Weeks of Treatment With Evinacumab Assessed by 18F-FDG SUVmax and SUVmean
gram/milliliter (g/ml)Placebo IV Q4W (DBTP)Evinacumab IV 15mg/kg Q4W (DBTP)
SUVmax: Baseline2.318 ± 0.61682.738 ± 0.6027
SUVmax: Change at Week 120.576 ± 1.06280.185 ± 0.5830
SUVmean: Baseline1.212 ± 0.25131.478 ± 0.2000
SUVmean: Change at Week 120.175 ± 0.2117-0.007 ± 0.2312
SecondaryDBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) Following 12 Weeks of Treatment With Evinacumab Assessed by Apparent Diffusion Coefficient (ADC)

In DW-MRI the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 cubic millimeter (mm\^3). Normal pancreas ADCs were considered as (1.77±0.32)\*103 square-millimeters per second (mm\^2/sec) while acute pancreatitis ADCs were (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring projected inflammatory changes in pancreas. DW-MRI was performed at baseline (placebo run-in period) and following 12 weeks of study treatment (double-blind treatment period) as a method to measure inflammation in the pancreas. Change from baseline in degree of pancreatic injury/inflammation through DW-MRI following 12 weeks of treatment with evinacumab assessed by ADC was reported.

Time frame:
Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP
Reported as:
Mean · Square-millimeters per second (mm^2/sec)
DBTP: Change From Baseline in Degree of Pancreatic Injury/Inflammation Through Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) Following 12 Weeks of Treatment With Evinacumab Assessed by Apparent Diffusion Coefficient (ADC)
Square-millimeters per second (mm^2/sec)Placebo IV Q4W (DBTP)Evinacumab IV 15mg/kg Q4W (DBTP)
DBTP: Baseline0.00144 ± 0.0003030.00154 ± 0.000257
DBTP: Change at Week 12-0.00007 ± 0.0001070.00001 ± 0.000133
SecondarySBTP: Change From Baseline to Degree of Pancreatic Injury/Inflammation Through DW-MRI Following 24 Weeks of Treatment With Evinacumab as Assessed by ADC

In DW-MRI, the random diffusion of water molecules occurring within intracellular, extracellular and intravascular spaces were measured, enabling detection of macroscopic soft tissue pathology such as edema, necrosis and fibrosis. The ADC was a principal metric quantified in DW-MRI experiments, where ADC values was mapped across a region of interest at a spatial resolution of \~3\*3\*5 mm\^3. Normal pancreas ADCs were considered as (1.77±0.32)\*103 mm\^2/sec while acute pancreatitis ADCs are (1.32±0.32)\* 103 mm\^2/sec showing a significant window for measuring the projected inflammatory changes in the pancreas. Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 24 weeks of treatment with evinacumab assessed by ADC was reported.

Time frame:
Baseline (Week 0 DBTP), Week 24 (SBTP)
Reported as:
Mean · mm^2/sec
SBTP: Change From Baseline to Degree of Pancreatic Injury/Inflammation Through DW-MRI Following 24 Weeks of Treatment With Evinacumab as Assessed by ADC
mm^2/secEvinacumab IV 15mg/kg Q4W (SBTP)
SBTP: Change From Baseline to Degree of Pancreatic Injury/Inflammation Through DW-MRI Following 24 Weeks of Treatment With Evinacumab as Assessed by ADC-0.00001 ± 0.000166
SecondaryTotal Evinacumab Concentration in Serum

Concentrations of total evinacumab in serum by time and DBTP treatment group reported

Time frame:
Up to 44 weeks
Reported as:
Mean · milligram per liter (mg/L)
Total Evinacumab Concentration in Serum
milligram per liter (mg/L)Placebo IV Q4W (DBTP)Evinacumab IV 15mg/kg Q4W (DBTP)
Week 0: Pre-DoseNA ± NANA ± NA
Week 0: End Of Infusion24.3 ± 97.0561 ± 203
Week 4: Pre-DoseNA ± NA73.6 ± 38.3
Week 4: End of Infusion0.334 ± 1.25590 ± 153
Week 8: Pre-DoseNA ± NA109 ± 57.2
Week 8: End of Infusion28.8 ± 104586 ± 119
Week 12: Pre-Dose0.00639 ± 0.0239124 ± 81.4
Week 12: End Of Infusion544 ± 159662 ± 146
Week 20: Pre-Dose113 ± 51.9160 ± 119
Week 20: End Of Infusion675 ± 146680 ± 199
Week 24: Post Last Dose 4 Weeks121 ± 76.7134 ± 77.2
Week 28: Post Last Dose 8 Weeks43.1 ± 47.840.2 ± 44.6
Week 36: Post Last Dose 16 Weeks0.239 ± 0.2501.98 ± 7.41
Week 44: Post Last Dose 24 Weeks0.0190 ± 0.04640.0680 ± 0.102
SecondaryTotal Angiopoietin-like (ANGPTL3) Concentration in Serum

Concentrations of total ANGPTL3 in serum by time and DBTP treatment group reported

Time frame:
Up to 44 weeks
Reported as:
Mean · mg/L
Total Angiopoietin-like (ANGPTL3) Concentration in Serum
mg/LPlacebo IV Q4W (DBTP)Evinacumab IV 15mg/kg Q4W (DBTP)
Week 0: Pre-Dose0.0929 ± 0.03130.105 ± 0.0327
Week 0: End of Infusion0.0950 ± 0.02560.258 ± 0.0745
Week 4: Pre-Dose0.111 ± 0.02720.265 ± 0.0932
Week 4: End of Infusion0.106 ± 0.02050.404 ± 0.132
Week 8: Pre-Dose0.114 ± 0.03330.307 ± 0.0758
Week 8: End of Infusion0.137 ± 0.09770.415 ± 0.0875
Week 12: Pre-Dose0.107 ± 0.02730.310 ± 0.0911
Week 12: End of Infusion0.250 ± 0.09400.394 ± 0.102
Week 20: Pre-Dose0.302 ± 0.09730.346 ± 0.101
Week 20: End of Infusion0.407 ± 0.1440.422 ± 0.118
Week 24: Post Last Dose 4 Weeks0.294 ± 0.09540.331 ± 0.113
Week 28: Post Last Dose 8 Weeks0.311 ± 0.07010.265 ± 0.0984
Week 36: Post Last Dose 16 Weeks0.134 ± 0.04870.193 ± 0.0969
Week 44: Post Last Dose 24 Weeks0.107 ± 0.03220.131 ± 0.0489
SecondaryNumber of Participants With Antidrug Antibodies (ADA)

ADA were classified as the following: 1) Negative any time (negative in ADA assay at all time points); 2) Pre-existing immunoreactivity (ADA positive response at baseline with all post treatment ADA results negative or ADA positive response at baseline with all post treatment responses less than 9-fold of baseline titer levels); 3) Treatment-boosted Response (ADA positive response in assay post first dose that is at least 9-fold over baseline titer levels, when baseline results were positive); 4) Treatment-emergent ADA response (ADA positive response post first dose, when baseline results were negative or missing). Number of participants with ADA by DBTP treatment group reported.

Time frame:
Up to 44 weeks
Reported as:
Count of participants · Participants
Number of Participants With Antidrug Antibodies (ADA)
ParticipantsPlacebo IV Q4W (DBTP)Evinacumab 15 mg/kg IV (DBTP)
Negative any Time1429
Pre-existing Immunoreactivity14
Treatment-boosted Response00
Treatment-emergent Response01
SecondaryDBTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the DBTP reported.

Time frame:
From first dose of DB treatment to day of last dose of DB treatment + 24 weeks (if not proceeding to SBTP) or up to day before first dose of SB treatment in SBTP
Reported as:
Count of participants · Participants
DBTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsPlacebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)
Participants with at least one TEAE1125
Participants with at least one serious TEAE34
SecondarySBTP: Number of Participants With TEAEs and Serious TEAEs

TEAEs are AEs that developed or worsened or became serious during the respective TEAE period. Number of participants who experienced a TEAE/serious TEAE during the SBTP reported.

Time frame:
From day of first SB study treatment to day of last SB treatment + 24 weeks
Reported as:
Count of participants · Participants
SBTP: Number of Participants With TEAEs and Serious TEAEs
ParticipantsEvinacumab 15 mg/kg (SBTP)
Participants with at least one TEAE38
Participants with at least one Serious TEAE15
SecondaryNumber of Participants With Liver Function Laboratory Abnormalities in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Total Bilirubin

The number of participants with laboratory abnormalities in ALT, AST, ALP, and total bilirubin that fell into the pre-defined potentially clinically significant value (PCSV) categories reported: ALT: greater than (\>)2 upper limit of normal (ULN) and baseline (BL) less than or equal to (\<=) 2 ULN, less than (\>) 3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline ≤ 10 ULN, \>20 ULN and baseline \<= 20 ULN; AST: \>2 ULN and baseline ≤ 2 ULN, \>3 ULN and baseline \<= 3 ULN, \>5 ULN and baseline \<= 5 ULN, \>10 ULN and baseline \<= 10 ULN, \>20 ULN and baseline \<= 20 ULN; ALP: \> 1.5 ULN and baseline \<= 1.5 ULN; Total Bilirubin (TB): \> 1.5 ULN and baseline \<= 1.5 ULN, \> 2 ULN and baseline \<= 2 ULN.

Time frame:
Baseline up to 44 weeks
Reported as:
Count of participants · Participants
Number of Participants With Liver Function Laboratory Abnormalities in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Total Bilirubin
ParticipantsPlacebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Evinacumab 15 mg/kg (SBTP)
ALT >2 ULN and <=3 ULN and <=2 ULN at baseline010
ALT >3 ULN and <=5 ULN and <=3 ULN at BL020
ALT >5 ULN and <=10 ULN and <=5 ULN at BL002
ALT 10 ULN and <=20 ULN and <=10 ULN at BL000
ALT >20 ULN and <=20 ULN at BL000
AST >2 ULN and <=3 ULN and <=2 ULN at BL020
AST >3 ULN and <=5 ULN and <=3 ULN at BL011
AST >5 ULN and <=10 ULN and <=5 ULN at BL001
AST >10 ULN and <=20 ULN and <=10 ULN at BL000
AST >20 ULN and <=20 ULN at BL000
Bilirubin >1.5 ULN - <=2 ULN and =<1.5 ULN at BL000
Bilirubin >2 ULN and =< 2.0 ULN at BL000
Alkaline Phosphatase >1.5 ULN and =< 1.5 ULN at BL002
(ALT>3ULN&TB>2ULN)&(ALT<=3ULN or TB<=2ULN) at BL000

Adverse events

Collected over From Day 1 up to Last Single-Blind (SB) dose + 168 days (24 weeks), up to approximately 44 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo IV Q4W (DBTP)0/16 (0%)3/16 (18.8%)11/16 (68.8%)
Evinacumab 15 mg/kg (DBTP)0/35 (0%)4/35 (11.4%)20/35 (57.1%)
Evinacumab 15 mg/kg (SBTP)0/15 (0%)4/15 (26.7%)13/15 (86.7%)
SBTP DB/SB Evinacumab IV 15mg/kg Q4W0/32 (0%)11/32 (34.4%)22/32 (68.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlacebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Evinacumab 15 mg/kg (SBTP)SBTP DB/SB Evinacumab IV 15mg/kg Q4W
Pancreatitis acuteGastrointestinal disorders2/163/354/158/32
IleusGastrointestinal disorders0/160/351/150/32
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/160/351/150/32
Abdominal painGastrointestinal disorders1/161/350/150/32
Abdominal pain upperGastrointestinal disorders0/160/350/151/32
Liver injuryHepatobiliary disorders0/160/350/151/32
Clostridium difficile infectionInfections and infestations0/160/350/151/32
Viral infectionInfections and infestations0/160/350/151/32
HypertriglyceridaemiaMetabolism and nutrition disorders0/160/350/151/32
Metabolic acidosisMetabolism and nutrition disorders0/160/350/151/32
Most frequent other events
Showing 10 of 71
Most frequent other events
EventPlacebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Evinacumab 15 mg/kg (SBTP)SBTP DB/SB Evinacumab IV 15mg/kg Q4W
Abdominal painGastrointestinal disorders1/164/352/154/32
DiarrhoeaGastrointestinal disorders1/161/352/150/32
NauseaGastrointestinal disorders1/161/352/151/32
Diabetes mellitusMetabolism and nutrition disorders1/161/352/151/32
HeadacheNervous system disorders2/164/352/152/32
Alanine aminotransferase increasedInvestigations0/162/352/150/32
Aspartate aminotransferase increasedInvestigations0/162/352/150/32
Urinary tract infectionInfections and infestations1/160/351/154/32
NasopharyngitisInfections and infestations1/162/351/153/32
Abdominal pain upperGastrointestinal disorders0/161/351/153/32

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received any double-blind study drug based on the treatment assigned (as randomized).

Age, Continuous
Age, Continuous(years)Placebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Total
Mean46.2 ± 13.1048.6 ± 10.2347.8 ± 11.13
Sex: Female, Male
Sex: Female, Male(Participants)Placebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Total
Female71724
Male91827
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Total
Hispanic or Latino246
Not Hispanic or Latino143145
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Total
American Indian or Alaska Native000
Asian156
Native Hawaiian or Other Pacific Islander000
Black or African American011
White122941
Other303
Fasting Triglycerides
Fasting Triglycerides(milligrams/deciliter (mg/dL))Placebo IV Q4W (DBTP)Evinacumab 15 mg/kg (DBTP)Total
Mean2303.8 ± 1503.812475.1 ± 1597.202421.4 ± 1555.50
08

Study locations

17 sites
  • Regeneron Research Facility
    Boca Raton, Florida 33434, United States
  • Regeneron Research Facility
    Atlanta, Georgia 30328, United States
  • Regeneron Research Facility
    Kansas City, Kansas 66160, United States
  • Regeneron Research Facility
    New York, New York 10029, United States
  • Regeneron Research Facility
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron Research Facility
    Pittsburgh, Pennsylvania 15261, United States
  • Regeneron Research Facility
    Dallas, Texas 75390, United States
  • Regeneron Research Facility
    Houston, Texas 77030, United States
  • Regeneron Research Facility
    Milwaukee, Wisconsin 53226, United States
  • Regeneron Research Facility
    Chicoutimi, Quebec G7H7K9, Canada
  • Regeneron Research Facility
    Québec, Quebec G1V4W2, Canada
  • Regeneron Research Facility
    Napoli, Campania 80131, Italy
  • Regeneron Research Facility
    Rome, 00161, Italy
  • Regeneron Research Facility
    Birmingham, B15 2TH, United Kingdom
  • Regeneron Research Facility
    London, NW3 2QG, United Kingdom
  • Regeneron Research Facility
    London, SE1 7EH, United Kingdom
  • Regeneron Research Facility
    Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Dec 2019, 18 months.

Results were first posted in Feb 2023, 3 years 1 month after primary completion. A results delay was requested in Dec 2020.

Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Mar 2, 2018
StartActual
Jun 7, 2018
Primary completionActual
Dec 17, 2019
CompletionActual
Jul 23, 2020
Results delay requested
Dec 16, 2020
Results first posted
Feb 16, 2023
Last update
Feb 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03452228
Responsible party
Sponsor
First posted
Mar 2, 2018
Start date
Jun 7, 2018
Primary completion
Dec 17, 2019
Completion
Jul 23, 2020
Results posted
Feb 16, 2023
Last update
Feb 16, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evinacumab

Start the discussion